Analyst Price Targets — CRBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 29, 2025 12:49 pm | — | Mizuho Securities | $39.00 | $17.12 | TheFly | Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho |
| October 20, 2025 12:32 pm | — | Piper Sandler | $51.00 | $16.86 | TheFly | Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler |
| October 20, 2025 10:56 am | — | H.C. Wainwright | $40.00 | $19.32 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) |
| December 2, 2024 9:09 am | Biren Amin | Piper Sandler | $35.00 | $17.82 | StreetInsider | Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight |
| October 21, 2024 6:17 am | Jeff Jones | Oppenheimer | $60.00 | $18.41 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| September 20, 2024 1:04 pm | Kalpit Patel | B.Riley Financial | $40.00 | $19.51 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at B.Riley |
| September 13, 2024 6:52 am | Graig Suvannavejh | Mizuho Securities | $74.00 | $51.58 | StreetInsider | Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| August 7, 2024 7:44 am | Jeff Jones | Oppenheimer | $88.00 | $48.30 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Raised to $88 at Oppenheimer |
| July 22, 2024 6:09 am | Andres Maldonado | H.C. Wainwright | $80.00 | $58.00 | TheFly | Corbus Pharmaceuticals resumed with a Buy at H.C. Wainwright |
| June 11, 2024 6:12 am | Brian Abrahams | RBC Capital | $82.00 | $43.87 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Raised to $82 at RBC Capital |
Latest News for CRBP
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025.
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRBP.
U.S. House Trading
No House trades found for CRBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.